Keynote

(EDU-K2) Oncology Pipeline 2022: Spotlight on Trends and Agents To Watch

Friday, October 14, 2022

10:00 AM – 11:15 AM ET

Location: Potomac D

ACPE UAN:0233-0000-22-049-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

Kaelyn C. Boss, PharmD

Clinical Consultant Pharmacist
Commonwealth Medicine University of Massachusetts Medical School - Shrewsbury, MA
Shrewsbury, MA
Bhavesh H. Shah, RPh, BCOP

Chief Pharmacy Officer Hematology/Oncology and Specialty Pharmacy
Boston Medical Center Health System
Boston, MA

Moderator(s)

JH

Jim R. Hopsicker, MBA

Vice President, Pharmacy
MVP Health Care
Schenectady, New York

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Gilead Sciences, Inc.

The cancer treatment pipeline has continually expanded over the past decade resulting in record breaking numbers of approvals in the United States. With more than 1,300 agents currently in development, the oncology pipeline shows no signs of slowing down. New gene and cell therapies, precision medicine, immuno-oncology combination therapies, and accelerating development timelines have been identified as disruptive trends toward addressing unmet needs and improving patient outcomes.

Faculty of this pipeline session will cover key agents newly approved or currently in late-stage development with a focus on novel mechanisms of action, cell and gene therapies, and personalized, mutation-driven treatments. The potential impact to current standards of care and what this may mean for payers will be discussed.

Learning Objectives:

At the completion of this activity, participants should be able to:

Identify recently approved and upcoming approvals of high-impact oncology specialty drugs for solid and hematologic malignancies.
Differentiate the mechanisms of action, indications, safety, and efficacy of newly approved and emerging oncology specialty medications.
Explain trends in key areas for growth in the oncology pipeline.
Discuss the impact of new and emerging approvals of oncology specialty medications on current standard of care, cost considerations, contracting, benefit formularies, and other managed care processes and stakeholders.